Tuesday, December 3 | 4:40 p.m.-4:50 p.m. | T8-SSNMMI04-2 | Room E353C
Here, attendees will find out whether high-resolution semiconductor PET/CT can compare with MRI in diagnosing the extent of breast cancer.
Akina Miyamoto, MD, of Shimane University in Matsue, Japan will discuss her team’s results, which found that the technique performed well in diagnosing breast cancer and that premenopausal women could benefit from this method.
The study consisted of 76 women with 82 total breast cancers who underwent high-resolution semiconductor PET/CT in the prone position. The women also underwent dynamic MRI prior to operation and without chemotherapy.
Based on the PET accumulation values of normal breast tissue, the team set four tumor thresholds for the PET/CT system: standard uptake value (SUV)mean+2 SD, SUVmean+3 SD, 1.5 SUVmean+2 SD, and 1.5 SUVmean+3 SD. It also measured semiautomatically for each threshold.
MRI successfully depicted all lesions, while WB-SiPM-PET/CT visualized all but one lesion, a ductal carcinoma in situ (DCIS) that was 6 mm in diameter. The researchers found a significant difference in the average SUVmean of normal breast tissue between premenopausal (0.865) and postmenopausal patients (0.767; p = 0.029). However, they found no significant differences between MRI and the 1.5 SUVmean+2 SD or 1.5 SUVmean+3 SD thresholds in terms of imaging size and pathological size.
Also, all imaging sizes by MRI and the four SUV thresholds showed a strong correlation with pathological size. And the percentage of pathological concordance rate of the 1.5 SUVmean+2 SD threshold proved to be highest (68.2%, p < 0.05) in premenopausal patients, while postmenopausal patients favored MRI (55.9%).
Find out what else the team found by attending this session.
